Market revenue in 2023 | USD 38,787.2 million |
Market revenue in 2030 | USD 73,546.7 million |
Growth rate | 9.6% (CAGR from 2023 to 2030) |
Largest segment | Transdermal patches |
Fastest growing segment | Drug Eluting Stents |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Photodynamic Therapy Devices, Transdermal Patches, Wound Care Products, Infusion Pumps, Orthopedic Combination Products, Drug Eluting Stents, Inhalers, Antimicrobial Catheters |
Key market players worldwide | Abbott Laboratories, Terumo Corp, Stryker Corp, Viatris Inc, Medtronic PLC, Boston Scientific Corp, Novartis AG ADR, Becton Dickinson & Co, Teleflex Inc, W L Gore & Associates |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug device combination products market will help companies and investors design strategic landscapes.
Transdermal patches was the largest segment with a revenue share of 22.96% in 2023. Horizon Databook has segmented the Europe drug device combination products market based on photodynamic therapy devices, transdermal patches, wound care products, infusion pumps, orthopedic combination products, drug eluting stents, inhalers, antimicrobial catheters covering the revenue growth of each sub-segment from 2018 to 2030.
Europe held the second-largest revenue share of the global drug device combination products market in 2023. The UK, France, Germany, Italy, and Spain are considered to be the major markets in this region. Growth in the region can be attributed to the increasing prevalence of chronic diseases, such as diabetes, pain, & respiratory conditions, which require regular medication.
According to the International Diabetes Federation, around 56.6 million adults in Europe were living with diabetes in 2022, and the number is expected to surge over the coming decade, highlighting the growing patient population. This is expected to drive the demand for drug-device combination products to improve medication compliance and overall treatment outcomes. Moreover, patients are increasingly looking for treatment options that are easy to use, painless, and noninvasive.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe drug device combination products market , including forecasts for subscribers. This continent databook contains high-level insights into Europe drug device combination products market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account